explore -WSS

explore

author：comprehensive 2025-10-01 01:50:36 - browse：819

JOSEPH PREZIOSO/AFP via Getty Images

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Thermo Fisher plant for manufacturing gene therapies to expand

explore

WSS

Why Sanofi got shellacked over its spinoff

Telehealth options flood the market as retailers push virtual care

Second xenotransplant done with gene

Eli Lilly to pay $200M for Beam’s stake in gene

CDC's new outbreak response network to include Northeastern

Drug for rare kidney disease narrowly misses mark in clinical trial

explore

explore

hotspot

Activists slam private health insurers over coverage restrictions

Medical student insurance fails on mental health care coverage

Trump demands the U.S. pay no more for drugs than other countries … again

Emergency workers more likely to restrain Black patients: study

Jerome Adams on the need for new antivirals for Covid

First Opinion Podcast: How to protect health care in times of war

Jerome Adams on the need for new antivirals for Covid

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

leisure time

Ukraine and a new approach to mental health in war

First Opinion Podcast: How to protect health care in times of war

Hospitals warn Medicare's drug payment fix is ‘unlawful’

The pink breast cancer awareness ribbon needs a redesign

Medtronic CEO on promising devices for diabetes, hypertension

CDC advisers recommend seasonal use of Pfizer RSV shot

Wikipedia

entertainment

explore

entertainment